CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

Rhea-AI Summary

CNS Pharmaceuticals is set to present at the Virtual Investor 2023 Companies to Watch Event on January 18, 2023, at 10:00 AM ET. CEO John Climaco will lead the presentation, showcasing the company's innovative pipeline for treating brain and central nervous system cancers, primarily focusing on their lead drug candidate, Berubicin. This anthracycline is notable for its ability to cross the blood-brain barrier and targets aggressive brain cancers like glioblastoma multiforme. A live webcast will be available on the company’s website, with a replay accessible for 90 days.

Live video webcast on Wednesday, January 18^th at 10:00 AM ET  

HOUSTON, January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

When will CNS Pharmaceuticals present at the Virtual Investor 2023 Companies to Watch Event?

CNS Pharmaceuticals will present on January 18, 2023, at 10:00 AM ET.

Who will represent CNS Pharmaceuticals during the presentation?

CEO John Climaco will represent CNS Pharmaceuticals during the presentation.

What is the focus of CNS Pharmaceuticals' presentation?

The presentation will focus on their pipeline of treatments for brain and CNS cancers, particularly their lead drug candidate, Berubicin.

How can I watch the CNS Pharmaceuticals presentation?

You can watch the presentation via a live video webcast on the company's website.

Will there be a replay available for the CNS Pharmaceuticals presentation?

Yes, a replay will be available two hours after the live presentation and accessible for 90 days.